This message was sent to ##Email##
|
|
|
|
|
|
Advertisement
|
|
|
University of Michigan Health System via Medical Xpress
As scientists learn more about which genetic mutations are driving different types of cancer, they're targeting treatments to small numbers of patients with the potential for big payoffs in improved outcomes. But even as we learn more about these driver mutations, a new study suggests the science might be leaving racial and ethnic minorities behind.
"Even when studies have a reasonable 'relative' representation of racial and ethnic minorities, the overall 'absolute' number of minorities examined may not be enough to detect small differences in the cancer's genome," says Daniel Spratt, M.D., assistant professor of radiation oncology at the University of Michigan Medical School.
READ MORE
CoC NCDB
The National Cancer Database (NCBD) Participant User File (PUF) application is accepting applications for site-specific files, which include cases diagnosed between 2004 and 2014. The application period closes Aug. 29 at 11:59 p.m. CST.
The NCDB PUF is a Health Insurance Portability and Accountability Act-compliant data file containing cases submitted to the Commission on Cancer's (CoC) NCDB and complies with the terms of the Business Associate Agreement between the American College of Surgeons and cancer programs accredited by the CoC (i.e., no patients or facilities can be identified). The PUF is designed to provide investigators at CoC-accredited cancer programs with a data resource they can use to review and advance the quality of care delivered to cancer patients through analyses of cases reported to the NCDB. Use of the PUF is not required to meet any CoC standards, but it is an opportunity provided as a benefit of accreditation.
Prospective applicants can find more information about the application process and data items available on the PUF web page.
Additional questions regarding the NCDB PUFs may be directed to the NCDB.
READ MORE
|
Promoted by
|
|
|
|
 |
Healio
Adenoma detection rates in colonoscopy-based and fecal immunochemical testing (FIT)-based colorectal cancer screening programs appeared positively and significantly correlated, according to a post-hoc analysis of the Spanish COLONPREV study. "Our study shows relevant results that will determine which is the minimum recommended adenoma detection rate in colorectal cancer screening programs based on fecal immunochemical tests," Joaquín Cubiella, MD, PhD, from the department of gastroenterology, Complexo Hospitalario de Ourense, Spain, told Healio Gastroenterology.
READ MORE
International Business Times
The growing epidemic of thyroid cancer reported over recent decades in several high-income nations can largely be put down to overdiagnosis, according to a new report by the International Agency for Research on Cancer in collaboration with the Aviano National Cancer Institute in Italy. Much of the time, tumors were diagnosed that were very unlikely to cause death during a person's lifetime.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text.
|
|
Medical University Vienna via Medical Xpress
MedUni Vienna researchers from the Department of Biomedical Imaging and Image-guided Therapy have conducted a meta analysis of more than 2,300 patients from 14 international studies and have been able to show, for the very first time, that if performed as a follow-up procedure in the event of equivocal breast cancer screening findings, magnetic resonance imaging (MRI) is able to rule cancer out with 100 percent certainty. "If the MRI scan does not reveal a tumor, any further risk can be virtually excluded. The affected women can then sleep peacefully once again — their fears are allayed," explain molecular biologist and radiologist Barbara Bennani-Baiti and radiologist Pascal Baltzer.
READ MORE
OncLive
The FDA approval of pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in August 2016 was extremely significant for this patient population, which previously had limited options following progression on a platinum-based chemotherapy.
The approval was based on the phase Ib KEYNOTE-012 study, which demonstrated that pembrolizumab had an overall response rate of 18 percent and a stable disease rate of 17 percent in patients with recurrent/metastatic HNSCC.
READ MORE
| |
SPONSORED CONTENT | Advertisement
|
|
Promoted by
|
|
|
|
 |
Specialty Pharmacy Times
A clinical trial found that introducing a CT screening for lung cancer in the U.K. could significantly reduce mortality in high-risk groups without causing individuals any unnecessary stress or anxiety.
In the U.K. lung cancer screening trial, researchers examined the long-term psychosocial outcomes for screenings. There were more than 4,000 women and men between the ages of 50 and 75 years old at high risk of lung cancer enrolled in the study.
READ MORE
Healthcare IT News
For meaningful use and MACRA, the government uses an IEEE description of interoperability that pre-dates today's crop of EHRs. Whether that will carry the healthcare industry into the future or not is a matter of some debate.
READ MORE
AJCC
If you are attending Clinical Congress, don't miss the ACS Theatre session on the new AJCC Cancer Staging Manual, Eighth Edition. The New AJCC TNM Staging System: Vision, What's New, and Preparing for Implementation will be presented by Editor-in-Chief Mahul Amin, MD, FCAP, who will provide an overview of the staging changes that go into effect Jan. 1, 2017. His presentation will cover the new staging systems, unique paradigms for existing systems, updated General Staging rules, prognostic factors and AJCC-endorsed risk-assessment models. The presentation will be on Tuesday, Oct. 18 from 11:15 - 11:40 am at the Theatre in the Exhibit Hall.
The AJCC Cancer Staging Manual, Eighth Edition, is scheduled for release at the end of October 2016.
READ MORE
|
|
Advertisement
 |
|
For the past 22 years, EduCare's mission has been to support Healthcare Professionals in educating breast cancer patients. We strive to offer products that are patient-friendly and up-to-date. Patient education increases compliance, reduces time constraints and promotes a partnership between patient and healthcare providers.
|
|
|
|
|
Advertisement
 |
|
Specialty Practice Management is a complete front- and back-office solution that offers a rapid return on your investment and improved satisfaction among your staff. Practices with 10 or fewer providers turn to this comprehensive solution to manage self-pay accounts and eliminate common mistakes.
|
|
|
|
ACS - CoC
Accreditation 101: Learning the Basics of CoC Accreditation and Standards will be held Sept. 9 in Chicago. This one-day program, taught by CoC surveyors and staff, provides an overview of the CoC accreditation standards and answers your questions about the standards and the survey process. This is the last time this program will be held in 2016.
OncLive
The treatment of patients with HER2-positive breast cancer has evolved quite a bit in recent years; however, there is still more than can be achieved, explains Chau T. Dang, MD.
"HER2-positive breast cancer was a very difficult disease to treat and now we have so many options, including taxane with trastuzumab and pertuzumab in the first-line and T-DM1 in the second-line setting," says Dang, a medical oncologist at Memorial Sloan Kettering Cancer Center. "But, what about beyond that?"
READ MORE
The Inquirer
When an influential federal panel recommended in 2012 that doctors omit prostate cancer screening from routine healthcare, it set off a firestorm.
Many men and their doctors seem to have heeded the advice, though the long-term implications won't be clear for a while, a new analysis suggests.
The advice of the U.S. Preventive Services Task Force appears to have led to a sizable drop in screening with the PSA blood test, and in diagnosis of early-stage prostate cancer, according to American Cancer Society researchers who have been monitoring the trends.
READ MORE
CoC - NAPBC
October is Breast Cancer Awareness Month. The National Accreditation Program for Breast Centers (NAPBC) and the Commission on Cancer (CoC) encourage you to promote Breast Cancer Awareness Month and use it as an opportunity to display and publicize your program's accreditation status with the CoC and NAPBC.
The NAPBC and the CoC have created a poster to use within your program and community.
How to access the poster:
Programs that are accredited solely by the NAPBC, use the Marketing Resources website link that was provided in your performance report email notification.
Programs that are accredited solely by the CoC or both the CoC and NAPBC, go to CoC Datalinks and click on Marketing Resources.
Please let us know about your celebration by sending photos and event information to Susan Rubin, business development manager, ACS Cancer Programs.
READ MORE
The AJCC announces five disease site webinars that are scheduled for summer and early fall this year. The webinars, offered at no cost, will provide highlights of the five most common site chapters for AJCC seventh edition staging and include: Melanoma, Lung, Breast, Colorectum and Prostate. There will be pre- and post-education quizzes to serve as a self-assessment for the information learned. The webinars will provide information on the uniqueness, differences, exceptions or special concerns for the disease sites.
Each lecture will contain the following topics:
Overview and Learning Objectives
Anatomy Affecting Stage
Classification Issues
Assigning T, N, M, Stage Group
Information and Questions on AJCC Staging and Summary
Melanoma and Lung are now available as recordings on the AJCC website. The third webinar (Breast) will be held on Aug. 31. The fourth webinar (Colorectum) will be held on Sept. 7. The fifth and final webinar (Prostate) will be held on Sept. 21. All the webinars will be recorded for anyone who is not able to attend the live session. Register now.
You can visit the AJCC website to learn more about the Disease Site webinars and stay informed.
READ MORE
For additional information, please complete the mailing list request form.
|
|
|
Advertisement
Advertisement
|
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
